GAD2 and nervous system disorder: Case reports have described severe neurological diseases in association with anti-GAD65 antibodies, such as limbic encephalitis and epilepsy, that barely responded to classical immunotherapy, such as steroids or intravenous immunoglobulins (IVIGs), and required more aggressive treatment with monoclonal antibodies, such as basiliximab or rituximab [77,78].